Edison Investment Research Comments on Halozyme Therapeutics on Multiple Value Drivers

In a report published Friday, Edison Investment Research analyst Jason Zhang commented on recent developments related to Halozyme Therapeutics HALO. In the report, Edison Investment Research noted, “With a positive CHMP opinion received for Herceptin SC, Halozyme is moved a step closer to being able to reap the full commercial potential of its rHuPH20 platform, which is being used to develop subcutaneous (sc) formulations of leading IV drugs for Roche and other partners. This opportunity currently drives Halozyme's valuation, but we contend that the market is ignoring certain key pipeline assets, notably PEGPH20, which is in a Phase II study in pancreatic cancer.” Halozyme Therapeutics closed on Wednesday at $7.69.